手机购彩

The special activity of "Quality Company of Shanghai Stock Exchange-I am a Shareholder" entered Hengrui Medicine Hengrui Medicine Today
In the afternoon of October 29, the special event of "Shanghai Stock Company Quality Bank-I am a Shareholder" sponsored by Shanghai Stock Exchange, Jiangsu Provincial Securities Regulatory Bureau, and Jiangsu Listed Companies Association went into Hengrui Medicine. Securities dealers, investors, About 50 people from the media came to Hengrui Medicine to learn more about the company's development and communicate face-to-face with company executives.
2019-11-01
Blockbuster | Hengrui Pharmaceutical's Class 1 New Drug Flurazole Pali Appears on the Market
Recently, Hengrui Pharmaceutical's new class 1 drug, fluzoparib, is based on single-arm, multi-center clinical study data for the treatment of recurrent ovarian cancer with BRCA1 / 2 pathogenic or suspected pathogenic mutations after previous second-line and above chemotherapy. Listed and accepted by the State Drug Administration
2019-10-31
Early success of pirlotinib phase III can significantly prolong progression-free survival in patients
Recently, a randomized, open, parallel, multicenter, phase III PHOEBE study of pirlotinib maleate and capecitabine in the treatment of advanced breast cancer was reviewed and confirmed by the Independent Data Supervision Committee (IDMC). Progression-free survival (PFS) assessed by IRC meets the pre-set mid-term analysis superiority determination criteria in advance, and the safety is acceptable
2019-10-25
2019 Fortune Global Top 50 Announced, Hengrui Medicine Ranks 14th
Recently, Fortune Magazine released a list of the world's top 50 companies, with a total of 16 Chinese companies on the list. Hengrui Medicine ranked 14th and is the only Chinese pharmaceutical company selected.
2019-10-23
Xiangyun Long, Secretary of the Lianyungang Municipal Party Committee, and Fang Wei, Mayor of the Lianyungang, and his party observed the production and construction of Hengrui Pharmaceutical Project
On October 8th, the Lianyungang Municipal Party Committee held the third quarter economic situation analysis meeting and the fourth quarter work mobilization meeting. Before the meeting, Xiang Xuelong, Secretary of the Municipal Party Committee and Director of the Standing Committee of the Municipal People's Congress, and deputy secretary of the Municipal Party Committee, Mayor Fang Wei and other four leaders of the city and other participants attended the Hengrui Pharmaceutical Innovative Drug Preparation Project and the Biomedical Industrial Park Base to observe the project production And construction situation
2019-10-09
CSCO Annual Conference 2019 ends, Hengrui Medicine releases several clinical research advances
From September 18th to 22nd, 2019, the 22nd National Conference of Clinical Oncology and the 2019 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) were held at Xiamen International Conference Center
2019-10-09
上一页 1 2 3 4 5 6 7 ... 12 下一页 Total 94 recordsPrevious page 1 2 3 4 5 6 7 ... 12Next page